GoAI
Get started
Cutia Therapeutics logo

Cutia Therapeutics

2487.HK

HKSEHealthcareBiotechnology

Open in GoAI

Latest quote

HK$1.92

−HK$0.03 · -1.54%

Aug 24, 2:23 PM HKTData delayed

2487.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, including medications for localized fat accumulation, advanced care for scalp disorders, treatments for a wide array of skin ailments, and topical pain management. Founded in 2019, the company's main headquarters are situated in Shanghai, China, complemented by additional offices located in Beijing, Wuxi, and Hong Kong.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CN
CEO
Lele Zhang
Listed since
Jun 12, 2023
Employees
304

Market position

Volume
114.2K
0.83× average
Average volume
138.31K
Average daily volume
Market cap
697.67M HKD
Beta
0.47
Market reference 1

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1655%-4649%-10953%-17257%Gross margin, FY2021: 79.00%Gross margin, FY2022: 69.84%Gross margin, FY2023: 51.60%Gross margin, FY2024: 51.31%Gross margin, FY2025: 58.25%Operating margin, FY2021: -8831.45%Operating margin, FY2022: -2720.43%Operating margin, FY2023: -392.12%Operating margin, FY2024: -162.78%Operating margin, FY2025: -91.81%Net margin, FY2021: -15681.11%Net margin, FY2022: -4890.34%Net margin, FY2023: -1426.91%Net margin, FY2024: -155.15%Net margin, FY2025: -101.20%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 79.00%. Gross margin FY2022 69.84%. Gross margin FY2023 51.60%. Gross margin FY2024 51.31%. Gross margin FY2025 58.25%. Operating margin FY2021 -8831.45%. Operating margin FY2022 -2720.43%. Operating margin FY2023 -392.12%. Operating margin FY2024 -162.78%. Operating margin FY2025 -91.81%. Net margin FY2021 -15681.11%. Net margin FY2022 -4890.34%. Net margin FY2023 -1426.91%. Net margin FY2024 -155.15%. Net margin FY2025 -101.20%.

Income trends

Revenue

336.15M HKD+20.22%

Operating income

−308.61M HKD+32.20%

Net income

−340.19M HKD+21.58%
Income trends across reported periods566.14M HKD−353.82M HKD−1.27B HKD−2.19B HKDRevenue, FY2021: 2.04M HKDRevenue, FY2022: 11.37M HKDRevenue, FY2023: 137.62M HKDRevenue, FY2024: 279.62M HKDRevenue, FY2025: 336.15M HKDOperating income, FY2021: −179.99M HKDOperating income, FY2022: −309.2M HKDOperating income, FY2023: −539.65M HKDOperating income, FY2024: −455.15M HKDOperating income, FY2025: −308.61M HKDNet income, FY2021: −319.58M HKDNet income, FY2022: −555.84M HKDNet income, FY2023: −1.96B HKDNet income, FY2024: −433.81M HKDNet income, FY2025: −340.19M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.04M HKD. Revenue FY2022 11.37M HKD. Revenue FY2023 137.62M HKD. Revenue FY2024 279.62M HKD. Revenue FY2025 336.15M HKD. Operating income FY2021 −179.99M HKD. Operating income FY2022 −309.2M HKD. Operating income FY2023 −539.65M HKD. Operating income FY2024 −455.15M HKD. Operating income FY2025 −308.61M HKD. Net income FY2021 −319.58M HKD. Net income FY2022 −555.84M HKD. Net income FY2023 −1.96B HKD. Net income FY2024 −433.81M HKD. Net income FY2025 −340.19M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue336.15M HKD279.62M HKD137.62M HKD11.37M HKD2.04M HKD
Cost of goods sold140.36M HKD136.15M HKD66.62M HKD3.43M HKD428K HKD
Gross profit195.79M HKD143.46M HKD71.01M HKD7.94M HKD1.61M HKD
Research and development148.65M HKD199.05M HKD215.71M HKD180.76M HKD110.56M HKD
Selling, general, and administrative355.75M HKD299.5M HKD255.16M HKD48.74M HKD16.55M HKD
Operating expenses504.4M HKD598.61M HKD597.98M HKD317.14M HKD181.6M HKD
Interest income6.36M HKD11.81M HKD23.41M HKD17.37M HKD6.11M HKD
Interest expense9.46M HKD10.86M HKD4.48M HKD1.73M HKD559K HKD
Depreciation and amortization30.68M HKD30.85M HKD42.48M HKD18.92M HKD9.79M HKD
Operating income−308.61M HKD−455.15M HKD−539.65M HKD−309.2M HKD−179.99M HKD
Net income−340.19M HKD−433.81M HKD−1.96B HKD−555.84M HKD−319.58M HKD

Company facts updated Aug 24, 2026.

2487.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.1

-4.23%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.74

-3.03%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$222.2

-2.54%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.40

-5.10%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.34

-5.26%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.35

-2.98%

ETFs holding 2487.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Dimensional World ex U.S. Core Equity 2 ETF logoDimensional World ex U.S. Core Equity 2 ETFDFAX
Market value
11.29K
Weight
0.00%
AUM
12.57B USD
Expense ratio
0.28%
Price / 1D
$38.16+0.82%

Continue in GoAI

Research 2487.HK

research.disclaimer